Ivelina Gueorguieva, PhD: Eli Lilly: Employment (Ongoing)
MIDD is used to identify dosing regimens, target population and informative endpoints (Marshall et al., 2023). A novel disease progression modeling platform in AD, including machine learning methods, characterized the relationship of disease-modifying biomarkers, such as amyloid plaque) and clinical score endpoints in early symptomatic AD using ADNI, and Donanemab clinical data. Multiple questions were addressed: 1) the natural amyloid plaque, and accumulation; 2) plaque re-accumulation following donanemab treatment discontinuation; 3) how does the rate of disease progression, following donanemab treatment, change with amyloid plaque reduction in early symptomatic AD participants. Using MIDD approach brings new insights in designing AD trials on treatment duration, dosing frequency and informative biomarker endpoints.
